WEI Qiufang,PAN Xinbo,MIAO Miaomiao.Pharmaceutical care and literature analysis of patients with decompensated cirrhosis complicated with Clostridioides difficile splenic abscess[J].ZHONGGUO YAOFANG,2026,37(14):1892-1897.
WEI Qiufang,PAN Xinbo,MIAO Miaomiao.Pharmaceutical care and literature analysis of patients with decompensated cirrhosis complicated with Clostridioides difficile splenic abscess[J].ZHONGGUO YAOFANG,2026,37(14):1892-1897.DOI: 10.6039/j.issn.1001-0408.2026.14.16.
Pharmaceutical care and literature analysis of patients with decompensated cirrhosis complicated with Clostridioidesdifficile splenic abscess
To provide a reference for pharmaceutical care in patients with decompensated cirrhosis complicated with
Clostridioides difficile
splenic abscess.
METHODS
2
Clinical pharmacists participated in the whole-process pharmaceutical care of one patient with the above complex conditions. Retrieved from CNKI, Wanfang Data, VIP, PubMed, Embase and Web of Science databases,relevant literature about
C. difficile
splenic abscess was collected and analyzed.
RESULTS
2
Based on the results of metagenomic next-generation sequencing,imaging characteristics, and tissue penetration of antimicrobial agents, the clinical pharmacist suggested switching from ceftriaxone combined with metronidazole to intravenous vancomycin combined with metronidazole. For the hypokalemia that developed in the patient, the clinical pharmacist suggested discontinuing Furosemide tablets and adding Potassium citrate granules. When the p
atient requested hospital discharge, the clinical pharmacist developed a post-discharge medication education plan. The physician adopted the clinical pharmacist’s recommendations. The patient improved after treatment without renal injury. Results of the literature analysis showed that among 11 involved patients,there were 9 males and 2 females,aged 32 to 90 years old,8 patients had a history of
C. difficile
infection. Vancomycin and metronidazole constituted the primary anti-infective regimens, and 3 patients died after treatment.
CONCLUSIONS
2
The clinical pharmacists ensured patients’ medication safety through pharmaceutical interventions including identifying the pathogen, optimizing anti-infective regimens, monitoring adverse drug reactions, and formulating a discharge medication education plan.
关键词
Keywords
references
Jiang X W , Yan J H , Huang H , et al . Development of novel parameters for pathogen identification in clinical metagenomic next-generation sequencing [J ] . Front Genet , 2023 , 14 : 1266990 .
Çorbaci K , Gürleyik M G , Aktaş A . Splenic abscess:treatment options in a disease with high mortality [J ] . BMC Infect Dis , 2024 , 24 ( 1 ): 1222 .
Arora N , Dhawan S . Splenic abscesses in the pediatric population:a literature review of an uncommon entity [J ] . Cureus , 2024 , 16 ( 7 ): e65607 .
AlZarooni N , AlBaroudi A , AlOzaibi L , et al . Splenic abscess as a possible sequela of COVID-19:a case series [J ] . Ann Saudi Med , 2021 , 41 ( 5 ): 307 - 311 .
Ooi D Q H , Ooi J Q C , Ooi L L P J . Splenic abscesses in the new millenium:a systematic review [J ] . ANZ J Surg , 2024 , 94 ( 10 ): 1702 - 1709 .
Zhao Y , Zhang W H , Zhang X . Application of metagenomic next-generation sequencing in the diagnosis of infectious diseases [J ] . Front Cell Infect Microbiol , 2024 , 14 : 1458316 .
Shi P , Liu J , Liang A , et al . Application of metagenomic next-generation sequencing in optimizing the diagnosis of ascitic infection in patients with liver cirrhosis [J ] . BMC Infect Dis , 2024 , 24 ( 1 ): 503 .
Angeli P , Bernardi M , Villanueva C , et al . EASL clinical practice guidelines for the management of patients with decompensated cirrhosis [J ] . J Hepatol , 2018 , 69 ( 2 ): 406 - 460 .
GUPTA P , TYAGI V , BHAKHRI B K , et al . Multiple splenic abscesses in an immunocompetent host [J ] . Indian J Pediatr , 2023 , 90 ( 8 ): 845 .
Komeno Y , Iida T , Kocha A , et al . Atypical splenic abscesses due to Clostridioides difficile [J ] . Am J Case Rep , 2022 , 23 : e936528 .
Van Ligten M J , Nalla A , Shihab S , et al . Rare presen-tation of splenic abscess secondary to Clostridioides difficile infection in a patient with systemic sclerosis:a case report [J ] . Cureus , 2025 , 17 ( 1 ): e76754 .
Saginur R , Fogel R , Begin L , et al . Splenic abscess due to Clostridium difficile [J ] . J Infect Dis , 1983 , 147 ( 6 ): 1105 .
Studemeister A E , Beilke M A , Kirmani N . Splenic abscess due to Clostridium difficile and Pseudomonas paucimobilis [J ] . Am J Gastroenterol , 1987 , 82 ( 4 ): 389 - 390 .
Stieglbauer K T , Gruber S A , Johnson S . Elevated serum antibody response to toxin A following splenic abscess due to Clostridium difficile [J ] . Clin Infect Dis , 1995 , 20 ( 1 ): 160 - 162 .
Kumar N , Flanagan P , Wise C , et al . Splenic abscess caused by Clostridium difficile [J ] . Eur J Clin Microbiol Infect Dis , 1997 , 16 ( 12 ): 938 - 939 .
Shedda S , Campbell I , Skinner I . Clostridium difficile splenic abscess [J ] . Aust N Z J Surg , 2000 , 70 ( 2 ): 147 - 148 .
Bedimo R , Weinstein J . Recurrent extraintestinal Clostridium difficile infection [J ] . Am J Med , 2003 , 114 ( 9 ): 770 - 771 .
Ball B Z , Briglia H A , Ivanick N M , et al . Perisplenic abscess due to Clostridium difficile :the first reported case in a decade [J ] . Infect Dis Clin Pract , 2015 , 23 ( 4 ): 218 - 220 .
Agha Y H , Seiler G , Millard J , et al . Clostridioides difficile beyond the colon:a case report [J ] . Sci J Immunol Immunother , 2019 , 3 ( 1 ): 9 - 11 .
Markantonis J E , Fallon J T , Madan R , et al . Clostridioides difficile infection:diagnosis and treatment challenges [J ] . Pathogens , 2024 , 13 ( 2 ): 118 .
Haedge F , Reuken P A , Reißing J , et al . Surrogate markers of intestinal permeability,bacterial translocation and gut-vascular barrier damage across stages of cirrhosis [J ] . Liver Int , 2025 , 45 ( 6 ): e70119 .
Freeman J , Sanders I M J G , Harmanus C , et al . Antimicrobial susceptibility testing of Clostridioides difficile :a dual-site study of three different media and three therapeutic antimicrobials [J ] . Clin Microbiol Infect , 2025 , 31 ( 6 ): 1011 - 1017 .
Zhang H F , Wang T , Fan Y X , et al . Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid:data from landrace pigs [J ] . J Antimicrob Chemother , 2026 , 81 ( 3 ): dkag063 .
Song X Q , Zeng M Z , Yang T , et al . Pharmacokinetics and customized dosing of vancomycin in adult patients with hematological malignancies:status,challenges,and opportunities [J ] . Pharmacology Res & Perspec , 2026 , 14 : e70218 .
Mpakogiannis K , Fousekis F S , Elemes S , et al . Extraintestinal manifestations of Clostridioides difficile infections:an overview [J ] . Antibiotics(Basel) , 2025 , 14 ( 7 ): 670 .
Ruiz-Pérez N C , Bayona-Pérez Y , Guzmán-Gutiérrez S L , et al . Metronidazole and vancomycin have a synergic effect,with plant extracts as helpful tools to combat Clostridioides difficile infections [J ] . Antibiotics(Basel) , 2025 , 14 ( 1 ): 54 .
He N , Su S , Ye Z K , et al . Evidence-based guideline for therapeutic drug monitoring of vancomycin:2020 update by the division of therapeutic drug monitoring,Chinese Pharmacological Society [J ] . Clin Infect Dis , 2020 , 71 ( Suppl. 4 ): S363 - S371 .
Um S H , Abuzgaia A , Rieder M . Comparison of the Liverpool causality assessment tool vs. the Naranjo scale for predicting the likelihood of an adverse drug reaction:a retrospective cohort study [J ] . Br J Clin Pharmacol , 2023 , 89 ( 8 ): 2407 - 2412 .